Physico chemical characterization of a novel anti-cancer agent and its comparison to Taxol®

Drug Development and Industrial Pharmacy

Volumn 39, Issue 1, 2013, Pages 89-101

  Shah, Amit K ^a,d   Wyandt, Christy M ^a,b,c   Stodghill, Steven P ^a,b  

^a School of Pharmacy   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c BELMONT UNIVERSITY   (United States)

^d Frontage Laboratories Inc   (United States)

Author keywords

Anti cancer; Membrane permeability; Preformulation; Stability; Thermal analysis

Indexed keywords

ANTINEOPLASTIC AGENT; JCA 112; OCTANOL; PACLITAXEL; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; MEMBRANE PERMEABILITY; PH; PHYSICAL CHEMISTRY; THERMAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; PACLITAXEL; PERMEABILITY;

EID: 84871196170     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.659187     Document Type: Article

References (36)

1. http://www.cancer.gov/cancertopics/factsheet/nci/ drugdiscovery/print. Accessed on 05 March 2011
2. Holmes FA. Current status of clinical trials with paclitaxel and docetaxel in Taxane Anticancer Agents: Basic science and current status. ACS Symposium Series. 1995. Washington, D.C.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1977;277:665-667.
4. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-568. (Pubitemid 23139860)
5. Jordan MA, Wendell K, Gardiner S. Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol)results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-825. (Pubitemid 26055472)
6. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1314. (Pubitemid 26301619)
7. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-233. (Pubitemid 27038278)
8. Yeung TK, Germond C, Chen X, Wang Z. The mode of action of Taxol: Apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res 1999;263:398-404. (Pubitemid 29467208)
9. Benet LZ, Goyan JE. Potentiometric determination of dissociation constants. J Pharm Sci 1967;56:665-680.
10. Moriguchi I. Simple methods for calculating octanol/water partition coefficient. Chem Pharm Bull 1992;40:127-130.
11. Hansch C, Taylor JB, Sammes PG. Comprehensive Medicinal Chemistry: Cumulative Subject Index and Drug Compendium. Oxford: Pergamon Press,1991.
12. Wohnsland F, Faller B. High-Throughput permeability pH profile and high-Throughput alkane/water log P with artificial membranes. J Med Chem 2001;44:923-930. (Pubitemid 32861617)
13. Yazdamian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compound. Pharm Res 1998;15:1490-1494. (Pubitemid 28427942)
14. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption process. J Med Chem 1998;41:1007-1010. (Pubitemid 28207375)
15. Liu H, Sabus C, Carter GT, Du C, Avdeef A, Tischler M. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm Res 2003;20:1820-1826. (Pubitemid 37449456)
16. Ruell JA, Tsinman O, Avdeef A. PAMPA - A drug absorption in vitro model 5. Unstirred water layer in iso-PH mapping assay and pKa fluxoptimized design (pOD-PAMPA). Eur J Pharm Sci 2003;20:393-402. (Pubitemid 37491433)
17. Sugano K, Nabuchi Y, Machida M, Aso Y. Prediction of human intestinal permeability using artificial membrane permeability. Int J Pharm 2003;257:245-251. (Pubitemid 36507050)
18. Dallas AJ, Carr PW. A thermodynamic and solvatochromic investigation of the effect of water on the phase-Transfer properties of octan-1-ol. J Chem Soc, Perkin Trans 2 1992;2155-2161.
19. Hefter GT. Alcohols with water. Solubility Data Series 1984;15:364-381.
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46:3-26. (Pubitemid 33653411)
21. Mwatamba K, Torrado S, Bandera C, Gordo PF, Torrado JJ. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 2004;272:29-36. (Pubitemid 38293008)
22. Datta S, Grant DJW. Crystal structures of drugs: Advances in determination, prediction and engineering. Nat Rev Drug Discovery 2004;3:42-57. (Pubitemid 38088697)
23. Morisette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. High-Throughput crystallization: Polymorphs, salts, co-Crystals and solvates of pharmaceutical solids. Adv Drug Delivery Rev 2004;56:275-300. (Pubitemid 38201426)
24. Roy S, Aitipamula S, Nangia A. Thermochemical analysis of Venlafaxine Hydrochloride polymorphs 1-5. Cryst Growth Des 2005;5:2268-2276. (Pubitemid 41619321)
25. Abu Zanat FZ, Qandil AM, Tashtoush BM. A promising codrug of nicotinic acid and ibuprofen for managing dislipidemia. I: Synthesis and in vitro evaluation. Drug Dev Ind Pharm 2011; 37:1090-1099.
26. Hidalgo IJ. Assessing the absorption of new pharmaceuticals. Current Topics Med Chem 2001;1:385-401.
27. Obata K, Sugano K, Machida M, Aso Y. Biopharmaceutics classification by high-Throughput solubility assay and PAMPA. Drug Dev Ind Pharm 2004;30:181-185. (Pubitemid 38420262)
28. Avdeef A, Artursson P, Neuhoff S, Lazarova L, Garasjo J, Travelin S. Caco-2 permeability of weakly basic drugs predicted with the double-Sink PAMPA pKaflux method. Eur J Pharm Sci 2005;24:333-349. (Pubitemid 40283516)
29. Tian J, Stella VJ. Degradation of paclitaxel and related compounds in aqueous solutions II: Nonepimerization degradation uder neutral to basic pH conditions. J Pharm Sci 2008;97:3100-3101.
30. Smrdel P, Grabnar I, Locatelli I, Cerne M, Andrensek S, Kovacic N, Kristl A, Bogataj M, Urleb U, Mrhar A. Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423-A new phthalimido-Desmuramyl-Dipeptide derivative with immunomodulationg activity. Drug Dev Ind Pharm 2009;35:1293-1301.
31. Wife RL, Tijhuis J. Library Quality Metrices. In: MS Chorghade, ed. Drug discovery and development: Drug development. Hoboken, NJ: John Wiley & Sons, Inc., 2007:265-278.
32. Kozikowski BA, Burt TM, Tirey DA, Williams LE, Kuzmak BR, Stanton DT, Morand KL, Nelson SL. The effect of room-Temperature storage on the stability of compounds in DMSO. J Biomol Screen 2003;8:205-209.
33. Dordunoo SK, Burt HM. Solubility and stability of taxol: Effects of buffer and cyclodextrins. Int J Pharm 1996;133:191-201. (Pubitemid 26163334)
34. Liggins RT, Hunter WL, Burt HM. Solid-State characterization of paclitaxel. J Pharm Sci 1997;86:1458-1463. (Pubitemid 28018330)
35. Sharma US, Balasubramanian SV, Straubinger RM. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrin. J Pharm Sci 1995;84:1223-1230.
36. http://www.jtbaker.com/msds/englishhtml/t4823.htm. Accessed on 12 February 2011.